Groupe d'Etude en Oncologie du Quebec

Title	A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Protocole ID	GO43860
ClinicalTrials.gov ID	NCT05581004
Cancer Type(s)	Non Small Cells - Lung
Phase	Phase I
Stage	Advanced or metastatic disease
Study Type	Clinical
Drug	RO7502175 en monothérapie et en association avec l'atézolizumab
Institution	CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS 3755 rue de la Côte Ste. Catherine, Montréal, QC, H3T 1E2
City
Principal Investigator	Dr. Wilson Miller
Coordinator	Karima Khebab 514-340-8222 poste 26187
Status	Recruiting
Activation Date	01-01-2024
Eligibility Criteria	Life expectancy at least 12 weeks Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Measurable disease according to Response Evaluation criteria in Solid Tumors (RECIST) Version 1.1 Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy Tumor Specimen availability
Exclusion Criteria	Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of study treatment Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment Active hepatitis B or C or tuberculosis Positive test for human immunodeficiency virus (HIV) infection Acute or chronic active Epstein-Barr virus (EBV) infection at screening Administration of a live, attenuated vaccine (e.g., FluMist) within 4 weeks before first RO7502175 infusion Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases Active or history of autoimmune disease Prior allogeneic stem cell or organ transplantation

Groupe d'étude en oncologie du Québec